Blog

Natalia Baran: The vital role of Doxorubicin in modern breast cancer treatment

Photo of Natalia Baran from faculty.mdanderson.org

Jan 23, 2025, 11:34

Natalia Baran: The vital role of Doxorubicin in modern breast cancer treatment

Natalia Baran , Research Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center, shared a post on LinkedIn:

“I am extremly happy to share more good news. Breast cancer remains one of the leading causes of death among women globally, driven by its aggressive nature and resistance to standard treatments.
Our latest review article published in Diseases and Research delves into the vital role of Doxorubicin (DOX)—a potent anticancer drug – in modern breast cancer treatment.

Key Highlights:

– Explores DOX’s ability to induce DNA damage and trigger reactive oxygen species.
– Analyzes its diverse mechanisms of cell death and immune response activation.
– Evaluates its role in monotherapy and combination therapies to enhance treatment efficacy.
– Discusses limitations and areas for future research, including innovations like nanoformulations.

DOX remains a cornerstone not only in breast cancer therapy but in treatment of other solid tumors and leukemia, our review sheds light on how to overcome challenges and maximize its potential in fighting this deadly disease.

Let’s continue the conversation! How do you see the future of DOX-based therapies evolving in breast cancer research and other tumors?

Big thank you and congratulations to very talented postdoctoral fellow Dr Biswajit Das for co-leading this efforts.”

Multifaced Anticancer Potential of Doxorubicin: Spotlight on Breast Cancer

Authors: Laxita Swain, Biswajit Das, Natalia Baran

Natalia Baran